Forest Buying Aptalis; Teva Bids For NuPathe Vs. Endo
Drug stocks were moving on merger news in the stock market today as Forest Laboratories (FRX) forestalled an IPO and NuPathe (PATH) looked to start a bidding war between Endo Health Solutions (ENDP) and Teva Pharmaceutical Industries (TEVA). Forest Labs agreed to pay $2.9 billion for Aptalis, a drugmaker that filed to go public on Dec. 26 after a major reworking by the private equity group TPG Capital. It traded as Axcan Pharma until 2007, when